US Patent No: 7,692,063

Number of patents in Portfolio can not be more than 2000

Production of foreign nucleic acids and polypeptides in sprout systems

ALSO PUBLISHED AS: 20060277634

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides systems and methods for producing a nucleic acid or protein in transgenic sprouted seedlings or sprouted seedlings engineered to transiently express a nucleic acid or protein of interest. The sprouted seedlings of the invention are grown in a contained, regulatable environment, wherein expression of a pharmaceutically active protein is controlled by an exogenously inducible promoter or a viral promoter. The sprouted seedlings may be eaten live or preferably harvested live to preserve the maximal biological activity of the nucleic acid or protein.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IBIO, INC.NEWARK, DE25

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ensley, Burt Newtown, PA 7 60
Mett, Vadim Newark, DE 33 84
Rabindran, Shailaja Newark, DE 12 45
Shamloul, Moneim Newark, DE 3 10
Yusibov, Vidadi Havertown, PA 56 197

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (3)
2004/0092,470 Dry powder oligonucleotide formualtion, preparation and its uses 26 2003
2006/0265,787 Recombinant carrier molecule for expression, delivery and purification of target polypeptides 17 2004
2007/0292,862 Enhanced transgene expression by co-expression with a suppressor of post-transcriptional gene silencing (PTGS) 6 2006
 
KENTUCKY BIOPROCESSING, INC. (3)
5,811,653 Viral amplification of recombinant messenger RNA in transgenic plants 21 1993
5,889,191 Viral amplification of recombinant messenger RNA in transgenic plants 11 1995
6,740,740 Process for isolating and purifying proteins and peptides from plant sources 19 2001
 
IMMUNOGEN, INC. (1)
5,639,641 Resurfacing of rodent antibodies 99 1992
 
PHYTOTECH, INC. (3)
5,728,300 Phytorecovery of metals using seedlings 12 1996
5,917,117 Inducing hyperaccumulation of metals in plant shoots 19 1996
5,853,576 Phytorecovery of metals using seedlings 15 1997
 
CLONTECH LABORATORIES (1)
6,410,317 Recombinase-based methods for producing expression vectors and compositions for use in practicing the same 28 2000
 
DYAX CORP. (2)
5,223,409 Directed evolution of novel binding proteins 1146 1991
5,403,484 Viruses expressing chimeric binding proteins 500 1993
 
KENTUCKY BIOPROCESSING, LLC (8)
5,316,931 Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes 97 1992
5,589,367 Recombinant plant viral nucleic acids 38 1994
5,965,794 Viral amplification of recombinant messenger RNA in transgenic plants 16 1994
5,866,785 Recombinant plant viral nucleic acids 29 1995
5,889,190 Recombinant plant viral nucleic acids 18 1995
6,054,566 Recombinant animal viral nucleic acids 8 1995
6,660,500 Production of peptides in plants as viral coat protein fusions 7 2001
6,841,659 Method for recovering proteins from the interstitial fluid of plant tissues 18 2003
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (6)
5,855,866 Methods for treating the vasculature of solid tumors 189 1994
5,965,132 Methods and compositions for targeting the vasculature of solid tumors 69 1994
5,877,289 Tissue factor compositions and ligands for the specific coagulation of vasculature 120 1995
6,004,555 Methods for the specific coagulation of vasculature 77 1995
6,093,399 Methods and compositions for the specific coagulation of vasculature 69 1995
6,261,535 Diagnostic methods for targeting the vasculature of solid tumors 79 1998
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,702,892 Phage-display of immunoglobulin heavy chain libraries 36 1995
 
THE TOLERX, INC. LIQUIDATING TRUST (1)
5,502,167 CDR grafted humanised chimeric T-cell antibodies 83 1994
 
BIOSITE INCORPORATED (2)
5,427,908 Recombinant library screening methods 262 1990
5,580,717 Recombinant library screening methods 281 1995
 
PLANT BIOSCIENCE LIMITED (3)
6,635,805 Methods and DNA constructs for gene silencing in transgenic plants 47 1999
6,369,296 Recombinant plant viral vectors 35 2000
6,531,647 Gene silencing methods 69 2000
 
MERCK SHARP & DOHME CORP. (2)
5,770,403 Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4 27 1995
5,705,154 Humanized monoclonal antibodies against human interleukin-4 48 1996
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (3)
5,888,789 Process for protein production in plants 32 1995
5,889,189 Process for protein production in plants 15 1995
* 5,994,628 Process for protein production in plants 17 1995
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
6,077,992 Binary viral expression system in plants 28 1998
6,632,980 Binary viral expression system in plants 15 1999
 
SBARRO INSITUTE FOR CANDER RESEARCH AND MOLECULAR MEDICINE (1)
6,596,698 Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing RB2/p130 7 2001
 
CORNELL UNIVERSITY (1)
6,858,426 Grapevine leafroll virus (type 2) proteins and their uses 7 2000
 
UNIVERSITY OF WASHINGTON (3)
5,654,184 Oral immunization by transgenic plants 36 1995
5,679,880 Oral immunization by transgenic plants 38 1995
5,686,079 Oral immunization by transgenic plants 34 1995
 
VENTRIA BIOSCIENCE (1)
6,127,145 Production of .alpha..sub.1 -antitrypsin in plants 8 1998
 
Genentech, Inc. (3)
4,816,567 Recombinant immunoglobin preparations 1706 1983
6,331,415 Methods of producing immunoglobulins, vectors and transformed host cells for use therein 231 1988
2003/0211,568 Secreted and transmembrane polypeptides and nucleic acids encoding the same 6 2001
 
GENPHARM INTERNATIONAL, INC. (6)
5,569,825 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes 446 1991
5,633,425 Transgenic non-human animals capable of producing heterologous antibodies 414 1992
5,545,806 Ransgenic non-human animals for producing heterologous antibodies 525 1992
5,661,016 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes 386 1993
5,625,126 Transgenic non-human animals for producing heterologous antibodies 413 1994
5,770,429 Transgenic non-human animals capable of producing heterologous antibodies 225 1995
 
NOVICI BIOTECH LLC (1)
2004/0088,757 Cytoplasmic gene inhibition or gene expression in transfected plants by tobraviral vector 6 2003
 
UTAH STATE UNIVERSITY (1)
6,399,317 Real time detection of antigens 18 1999
 
BAYER CROPSCIENCE N.V. (1)
2003/0135,882 Methods and means for delivering inhibitory RNA to plants and applications thereof 19 2002
 
ICON GENETICS GMBH (2)
2005/0091,706 Recombinant viral switches for the control of gene expression in plants 18 2004
2007/0300,330 Two-Component Rna Virus-Derived Plant Expression System 7 2005
 
Schilperoort; Robbert Adriaan (1)
5,464,763 Process for the incorporation of foreign DNA into the genome of dicotyledonous plants 85 1993
 
UniCrop Ltd (1)
2003/0097,678 Process for converting storage reserves of dicot seeds into compositions comprising one or more gene products 20 2002
 
XOMA TECHNOLOGY LTD. (2)
5,693,493 Modular assembly of antibody genes, antibodies prepared thereby and use 51 1995
5,698,417 Modular assembly of antibody genes, antibodies prepared thereby and use 44 1995
 
PURDUE RESEARCH FOUNDATION (1)
5,874,087 Modified plant viruses as vectors 15 1995
 
CALGENE, INC. (2)
4,956,282 Mammalian peptide expression in plant cells 150 1985
5,750,871 Transformation and foreign gene expression in Brassica species 35 1995
 
LARGE SCALE BIOLOGY CORPORATION (2)
5,922,602 Cytoplasmic inhibition of gene expression 24 1994
6,376,752 Cytoplasmic inhibition of gene expression in a plant 7 1999
 
TEIJIN LIMITED (1)
4,935,496 Mouse-human chimaeric immunoglobulin heavy chain specific for the call antigen 36 1985
 
DOW AGROSCIENCES LLC (4)
5,500,360 RNA transformation vector 53 1994
5,602,242 Hybrid RNA virus 45 1995
5,846,795 RNA transformation vector 21 1995
5,627,060 Hybrid RNA virus 29 1995
 
The Scripps Research Institute (4)
5,658,727 Heterodimeric receptor libraries using phagemids 214 1994
5,667,988 Methods for producing antibody libraries using universal or randomized immunoglobulin light chains 61 1994
5,759,817 Heterodimeric receptor libraries using phagemids 43 1994
6,852,319 Method of use of transgenic plant expressed antibodies 10 2000
 
EXXON CHEMICAL PATENTS INC. (1)
5,565,332 Production of chimeric antibodies - a combinatorial approach 411 1994
 
THOMAS JEFFERSON UNIVERSITY (4)
6,042,832 Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins 28 1996
6,051,239 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents 21 1997
6,297,357 prb2/p130 peptide inhibitors of cdk2 kinase activity 7 1998
6,448,070 Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid 9 1999
 
APPLIED MOLECULAR EVOLUTION, INC. (1)
5,698,426 Surface expression libraries of heteromeric receptors 216 1995
 
THE TEXAS A&M UNIVERSITY SYSTEM (2)
5,491,076 Expression of foreign genes using a replicating polyprotein producing virus vector 31 1993
5,766,885 Potyvirus vectors for the expression of foreign genes 61 1995
 
PROTEIN DESIGN LABS, INC. (4)
5,530,101 Humanized immunoglobulins 863 1990
5,585,089 Humanized immunoglobulins 888 1995
5,693,761 Polynucleotides encoding improved humanized immunoglobulins 385 1995
5,693,762 Humanized immunoglobulins 705 1995
 
ROCHE MOLECULAR SYSTEMS, INC. (1)
4,683,202 Process for amplifying nucleic acid sequences 3259 1985
 
MEDICAL RESEARCH COUNCIL (2)
5,545,807 Production of antibodies from transgenic animals 426 1994
5,733,743 Methods for producing members of specific binding pairs 295 1994
 
GPC BIOTECH INC. (1)
6,015,692 CDC37 cell-cycle regulatory protein and uses related thereto 8 1997
 
NOVOZYMES A/S (1)
6,500,644 Method for in vivo production of a mutant library in cells 8 2000
 
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, THE, NON-PROFIT CORP. OF GA. (1)
5,447,858 Heat shock promoter and gene 20 1984
 
KYOWA HAKKO KIRIN CO., LTD. (1)
5,750,078 Process for producing humanized chimera antibody 44 1995
 
MONSANTO COMPANY (1)
5,565,347 Transformation and foreign gene expression with plant species 41 1993
 
PESTAX LIMITED (1)
5,175,102 Modification of plant viruses or their effects 10 1989
 
UNIVERSITY OF SOUTH CAROLINA (2)
5,939,541 Method for enhancing expression of a foreign or endogenous gene product in plants 18 1997
6,395,962 Enhancing expression of a silenced target sequence in plants using plant viral enhancers and amplicons 9 1999
 
MERCK PATENT GMBH (1)
5,558,864 Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies 108 1992
 
INB:BIOTECHNOLOGIES, INC. (1)
2007/0178,148 Preparations of growth hormone 6 2006
 
IBIO, INC. (7)
7,012,172 Virus induced gene silencing in plants 6 2002
2004/0093,643 Production of pharmaceutically active proteins in sprouted seedlings 17 2002
2005/0026,291 System for expression of genes in plants 18 2004
2005/0114,920 Expression of foreign sequences in plants using transactivation system 13 2004
2006/0085,871 Systems and methods for clonal expression in plants 7 2005
2006/0277,634 Production of foreign nucleic acids and polypeptides in sprout systems 6 2006
2008/0241,931 System For Expression of Genes In Plants 5 2008
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
IBIO, INC. (4)
8,058,511 System for expression of genes in plants 2 2008
* 2011/0070,609 Production of Foreign Nucleic Acids and Polypeptides in Sprout Systems 1 2010
8,597,942 System for expression of genes in plants 1 2011
8,951,791 System for expression of genes in plants 0 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 6, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 6, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00